DR. CATRIONA JAMIESON, M.D./PH.D
Osteopathic Medicine at Health Sciences Dr, La Jolla, CA
License number
California A67419
Category
Osteopathic Medicine
Type
Internal Medicine
License number
California A67419
Category
Osteopathic Medicine
Type
Hematology & Oncology
Address
Address
3855 Health Sciences Dr, La Jolla, CA 92093
Phone
(858) 822-6100
(858) 822-6189 (Fax)
(858) 822-6189 (Fax)
Organization information
See more information about CATRIONA JAMIESON at bizstanding.comCatriona Jamieson MD,PHD
3855 Health Sciences Dr, La Jolla, CA 92037
Industry:
Internist
Phone:
(858) 822-6100 (Phone)
Description:
There are 23 doctors at this site. Surgery is not performed at this site.
Catriona Helen Macleod Jamieson
Professional information
Dr. Catriona Jamieson, La Jolla CA - MD (Doctor of Medicine)
Specialties:
Hematology
Address:
UCSD Morris Cancer Center
3855 Health Sciences Dr STE 1102, La Jolla 92093
(858) 822-6100 (Phone)
3855 Health Sciences Dr STE 1102, La Jolla 92093
(858) 822-6100 (Phone)
Certifications:
Hematology, 2001, Internal Medicine, 1998
Awards:
Healthgrades Honor Roll
Languages:
English, Chinese, Russian, Spanish
Education:
Medical School
University Of British Columbia Faculty Of Medicine
Graduated: 1995
University Of British Columbia Faculty Of Medicine
Graduated: 1995
Catriona Jamieson, La Jolla CA
Specialties:
Internal Medicine, Hematology, Hematology & Oncology, Medical Oncology
Work:
Urgentcare San Diego Moores Cancer Center
3855 Health Sciences Dr, La Jolla, CA 92093
3855 Health Sciences Dr, La Jolla, CA 92093
Education:
University Of British Columbia Faculty Of Medicine (1995)
Catriona Jamieson, La Jolla CA
Specialties:
Internist
Address:
3855 Health Sciences Dr, La Jolla, CA 92093
Compositions And Methods For Determining Cancer Stem Cell Self-Renewal Potential
US Patent:
2011005, Mar 10, 2011
Filed:
Jun 23, 2010
Appl. No.:
12/821738
Inventors:
Catriona H. JAMIESON - La Jolla CA, US
Annelie SCHAIRER - Escondido CA, US
Ifat GERON - San Diego CA, US
Annelie SCHAIRER - Escondido CA, US
Ifat GERON - San Diego CA, US
Assignee:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA - Oakland CA
International Classification:
C12Q 1/68, C12Q 1/02
US Classification:
435 6, 435 29
Abstract:
In alternative embodiments, the invention provides compositions and methods for determining the self-renewal potential of a cancer stem cell (CSC) through analysis of the cross-talk between cell self-renewal pathways leading to deregulation and enhanced self-renewal of the CSC, or for predicting the drugability (susceptibility to a drug) of a CSC, and/or for predicting the progression of a cancer that corresponds to the CSC, the method comprising detecting and quantifying in CSCs one or more B-cell lymphoma-2 (Bcl-2) family protein isoform(s) or transcripts (mRNAs, messages) encoding one or more Bcl-2 family protein(s) or protein isoform(s) thereof. In alternative embodiments, the invention provides compositions and methods to determine and measure the levels of Wnt, glycogen synthase kinase-3 beta (GSK-3 beta), glycogen synthase kinase-3 alpha (GSK-3 alpha), and/or Sonic Hedgehog Homolog (SHH or Shh) family proteins and alternatively spliced transcripts (mRNAs), and Wnt, GSK3beta, GSK3alpha and/or Shh family protein and alternatively spliced transcript ratios in cancer cells, e.g., stem cells, e.g., CSCs, for diagnostic, drug discovery and prognostic purposes.
Wnt Signaling Inhibitors, And Methods For Making And Using Them
US Patent:
8304408, Nov 6, 2012
Filed:
May 15, 2008
Appl. No.:
12/600996
Inventors:
Wolfgang Wrasidlo - La Jolla CA, US
Catriona H. Jamieson - La Jolla CA, US
Dennis Carson - La Jolla CA, US
Tadeusz F. Molinski - La Jolla CA, US
Desheng Lu - La Jolla CA, US
Catriona H. Jamieson - La Jolla CA, US
Dennis Carson - La Jolla CA, US
Tadeusz F. Molinski - La Jolla CA, US
Desheng Lu - La Jolla CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A61K 31/35, A61P 35/02
US Classification:
51421206, 51421207
Abstract:
The invention provides dBHD-based compositions and dBHD analog compositions, and pharmaceutical compositions comprising them, e. g. , in the form of liposomes and nanoparticles comprising them, and methods of making and using them. In one embodiment, these dBHD analogs are used to inhibit a dysfunctional stem cell and/or a cancer (tumor) stem cell.
Methods Of Identifying And Isolating Stem Cells And Cancer Stem Cells
US Patent:
2007023, Oct 11, 2007
Filed:
May 2, 2007
Appl. No.:
11/799817
Inventors:
Catriona Jamieson - La Jolla CA, US
Laurie Ailles - Palo Alto CA, US
Tannishtha Reya - Chapel Hill NC, US
Irving Weissman - Stanford CA, US
Laurie Ailles - Palo Alto CA, US
Tannishtha Reya - Chapel Hill NC, US
Irving Weissman - Stanford CA, US
International Classification:
C12Q 1/02, C12N 15/09, C12Q 1/68
US Classification:
435006000, 435029000, 435455000
Abstract:
Methods and compositions are provided for the identification of stem cells and cancer stem cells. β-catenin is also identified as a target for the development of therapeutic moieties against hematopoietic tumors, i.e. leukemia and lymphoma cells, which may include screening assays directed at β-catenin, or members of the β-catenin signaling pathway. Cellular proliferation in hematopoietic cells can be altered by introducing stabilized β-catenin into a hematopoietic cell that is altered in its ability to undergo apoptosis but which is not fully transformed. The immortalized cells are useful in screening assays, and in the analysis of pathways by which hematopoietic cells undergo transformation.